Therapeutic compositions for addressing physiological stresses and aging include an immune modulator and one or more adaptogenic nutrients. Some non-limiting examples of immune modulators include as transfer factor, low molecular weight fraction immune modulators and/or other low molecular weight fractions of colostrum, egg or any other source of transfer factor or low molecular weight fraction immune modulators. Methods for administering immune modulators and adaptogenic nutrients to a subject to address the effects of physiological stresses and aging in the body of the subject, such as inflammatory responses, are also disclosed.

A method for treating the gastro-intestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

A method for treating the gastro-intestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

The present invention relates generally to a feed supplement preparation for administration to ruminant animals and, more particularly, to a formulation for an oral bovine supplement for neonatal calves that delivers naturally occurring caffeine, in a stable liquid form of elevated viscosity and optionally antioxidants and other electrolytes. A 10-40 ml liquid dose of the supplement containing green tea extract delivers a concentrated amount of caffeine of about 100-400 mg to the neonatal calf.

Coronavirus Disease 2019 (COVID-19) remains a threat with the emergence of new variants, especially Delta and Omicron, without specific effective therapeutic drugs. The present invention provides a method and a composition for preventing and treating COVID-19 (SARS-CoV-2) coronavirus infection which includes administering to a subject in need thereof one or more therapeutically effective doses of Virofree which comprises a pharmaceutically acceptable combination of grape seed extract, acerola cherry extract, olive leaf extract, marigold extract, green tea extract, pomegranate extract, yeast beta-glucan and soya bean extract for a treatment period.

Coronavirus Disease 2019 (COVID-19) remains a threat with the emergence of new variants, especially Delta and Omicron, without specific effective therapeutic drugs. The present invention provides a method and a composition for preventing and treating COVID-19 (SARS-CoV-2) coronavirus infection which includes administering to a subject in need thereof one or more therapeutically effective doses of Virofree which comprises a pharmaceutically acceptable combination of grape seed extract, acerola cherry extract, olive leaf extract, marigold extract, green tea extract, pomegranate extract, yeast beta-glucan and soya bean extract for a treatment period.

Coronavirus Disease 2019 (COVID-19) remains a threat with the emergence of new variants, especially Delta and Omicron, without specific effective therapeutic drugs. The present invention provides a method and a composition for preventing and treating COVID-19 (SARS-CoV-2) coronavirus infection which includes administering to a subject in need thereof one or more therapeutically effective doses of Virofree which comprises a pharmaceutically acceptable combination of grape seed extract, acerola cherry extract, olive leaf extract, marigold extract, green tea extract, pomegranate extract, yeast beta-glucan and soya bean extract for a treatment period.

The present disclosure relates to a composition for ameliorating a circulatory system disease, which contains a green tea extract with modified ingredient content. According to the present disclosure, it is possible to effectively prevent, ameliorate and treat circulatory system diseases without side effects and, thereby, to greatly help patients with circulatory system diseases and contribute to the development of related industries.

The present disclosure relates to a composition for ameliorating a circulatory system disease, which contains a green tea extract with modified ingredient content. According to the present disclosure, it is possible to effectively prevent, ameliorate and treat circulatory system diseases without side effects and, thereby, to greatly help patients with circulatory system diseases and contribute to the development of related industries.

A Camellia extract obtained by extracting by ultrasound a powder of Camellia japonica flowers, the powder being impregnated with a fatty substance or a mixture of fatty substances, with a hydroalcoholic solvent, and a cosmetic composition including such an extract having in particular a soothing effect for the skin. Also, a non-therapeutic use thereof for soothing the skin.